| 12:08p | European ADRs Move Higher in Monday Trading | MT |
| 05/15 | Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU | MT |
| 05/13 | UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating | MT |
| 05/11 | New class of cancer drugs down, not out, after Roche trial setback - analysts | RE |
| 05/11 | Pfizer's $11.6 billion Biohaven buy could spark more biotech deals | RE |
| 05/11 | European ADRs Move Sharply Higher in Wednesday Trading | MT |
| 05/11 | BIONTECH : Goldman Sachs sticks Neutral | MD |
| 05/10 | TRANSCRIPT : Gilead Sciences, Inc. Presents at Bank of America 2022 Healthcare Conference,.. | CI |
| 05/10 | TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C.. | CI |
| 05/10 | Morgan Stanley Lowers BioNTech SE's Price Target to $195 From $197, Equalweight Rating .. | MT |
| 05/10 | What you need to know about the coronavirus right now | RE |
| 05/09 | BIONTECH : JP Morgan reiterates its Neutral rating | MD |
| 05/09 | SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close | MT |
| 05/09 | SECTOR UPDATE : Health Care Stocks Slide with Broader Monday Markets | MT |
| 05/09 | BioNTech Q1 Results Top Street Estimates; Shares Gain | MT |
| 05/09 | UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating | MT |
| 05/09 | BIONTECH : Jefferies reiterates its Neutral rating | MD |
| 05/09 | BioNTech Q1 Earnings, Revenue Surge; Shares Rise Pre-Bell | MT |
| 05/09 | TRANSCRIPT : BioNTech SE, Q1 2022 Earnings Call, May 09, 2022 | CI |
| 05/09 | Equities Slide Pre-Bell as US Signals More Losses; Europe, Asia Retreat | MT |
| 05/09 | Wall Street Leans Back Pre-Bell; Europe Off, Asia Down | MT |
| 05/09 | BioNTech Reiterates 2022 Vaccine Revenue Guidance After Boost In Q1 Earnings | MT |
| 05/09 | COVID vaccine makers shift focus to boosters | RE |
| 05/09 | Earnings Flash (BNTX) BIONTECH SE Posts Q1 EPS EUR14.24 | MT |
| 05/09 | Earnings Flash (BNTX) BIONTECH SE Posts Q1 Revenue EUR6.38B | MT |
| 05/09 | BioNTech SE Proposes Special Cash Dividend | CI |
| 05/09 | BioNTech SE Reiterates Earnings Guidance for the Year 2022 | CI |
| 05/09 | BioNTech SE Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/09 | BioNTech Revenue, Profit More Than Triple in 1Q; Backs 2022 Outlook | DJ |
| 05/06 | WuXi AppTec Co Announces Dividend for 2021, Expected Payable Date of H Shareholders Jun.. | CI |
| 05/06 | WuXi AppTec Co., Appoints Minzhang Chen as Director | CI |
| 05/06 | Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $368 From $329, Mainta.. | MT |
| 05/06 | Wells Fargo Adjusts Vertex Pharmaceuticals' Price Target to $305 From $300, Reiterates .. | MT |
| 05/06 | Baird Downgrades Vertex Pharmaceuticals to Neutral From Outperform, Adjusts Price Targe.. | MT |
| 05/06 | RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $267 From $274, Keeps Sec.. | MT |
| 05/06 | Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $242 From $249, Maintai.. | MT |
| 05/05 | Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 Revenue $2.1B, vs... | MT |
| 05/05 | Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 EPS $3.52, vs. Str.. | MT |
| 05/05 | TRANSCRIPT : Vertex Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 05, 2022 | CI |
| 05/05 | Vertex Pharmaceuticals Q1 Results Rise; Reaffirms 2022 Product Revenue Guidance | MT |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Declaration of Voting Results by Gilead Sciences, Inc | CI |
| 05/05 | Vertex Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ende.. | CI |
| 05/05 | Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 | CI |
| 05/05 | EARNINGS REACTION HISTORY : Vertex Pharmaceuticals, 55.6% Follow-Through Indicator, 2.6% S.. | MT |
| 05/05 | RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $658 From $647, Maintains.. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
